Artificial Intelligence And The Future Of Medicine

| December 12, 2018

article image
Washington University researchers are working to develop artificial intelligence (AI) systems for health care, which have the potential to transform the diagnosis and treatment of diseases, helping to ensure that patients get the right treatment at the right time. In a new Viewpoint article published Dec. 10 in the Journal of the American Medical Association (JAMA), two AI experts at Washington University School of Medicine in St. Louis — Philip Payne, PhD, the Robert J. Terry Professor and director of the Institute for Informatics; and Thomas M. Maddox, MD, a professor of medicine and director of the Health Systems Innovation Lab — discuss the best uses for AI in health care and outline some of the challenges for implementing the technology in hospitals and clinics.

Spotlight

Valens Molecules Private Limited

Valens Molecules (formerly Posh Chemicals) is a world class manufacturing company partnering with market leaders to offer pharmaceutical products and services.Established in 1994.

OTHER ARTICLES

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Spotlight

Valens Molecules Private Limited

Valens Molecules (formerly Posh Chemicals) is a world class manufacturing company partnering with market leaders to offer pharmaceutical products and services.Established in 1994.

Events